Back to search results

Messaging to Providers About Treatment of Heart Failure at Inova

This study is looking at whether a special alert in the electronic health record (EHR) can help doctors prescribe the right medications for patients with heart failure with reduced ejection fraction (HFrEF). HFrEF means your heart's main pumping chamber doesn't squeeze as well as it should. The alert will pop up for doctors when they open your medical record, reminding them about guideline-recommended heart failure medications you might not be taking. The goal is to see if this alert leads to more patients receiving these important medications within 30 days. You could be eligible if you are over 18, have HFrEF (left ventricular ejection fraction ≤40%), and are seen by a cardiologist at an Inova clinic or hospital. The study status is currently unclear.

Study design
This is a randomized, single-blind study involving approximately 5000 participants. Some doctors will receive the electronic health record alert, while others will provide usual care.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The study will measure the use of guideline-directed medical therapy (GDMT) 30 days after randomization.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05433220

PRagmatic Trial Of Messaging to Providers About Treatment of Heart Failure at Inova

Recruiting
NAAges 18+Interventional
Inova Health Care Services
~5,000 participants
Updated 2026-07-13 on ClinicalTrials.gov
What's tested:Best Practice Advisory using Electronic Health Record

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Increased use of GDMT in patients with Heart Failure with Reduced Ejection Fraction
Measured over 30 days after randomization

Conditions

Heart Failure

Explore related trials

Heart Failure

NCT05433220

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Inova Health System

    Falls Church, Virginiastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Mitchell Psotka, MD, PhD · PRINCIPAL_INVESTIGATOR · Inova Health Care Services

Who to contact

Matthew G Dimond, BS
[email protected]
7037762828
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age\>18 Years
Seen by a Cardiologist in an Inova clinic or Inova hospital setting
Left Ventricular Ejection Fraction ≤40%

Exclusion

Opted out of EHR-based research
Hospice care
Already receiving maximally titrated doses of each of the four classes of evidence- based HFrEF medical therapy
Prior heart transplant

What this trial measures

  • Increased use of GDMT in patients with Heart Failure with Reduced Ejection Fraction30 days after randomization

    The primary outcome for the trial will be the proportion of patients with HFrEF who have an increase in the number of prescribed evidence-based therapies for HFrEF (beta-blockers, ACE-I/ARB/ARNI, MRA, SGLT2i) 30 days after randomization.